Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Capital Employed (2021 - 2025)

ARS Pharmaceuticals' Return on Capital Employed history spans 5 years, with the latest figure at 0.58% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 58.0% year-over-year to 0.58%; the TTM value through Dec 2025 reached 0.58%, down 58.0%, while the annual FY2025 figure was 0.6%, 60.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.58% at ARS Pharmaceuticals, down from 0.29% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.1% in Q3 2022 and bottomed at 0.58% in Q4 2025.
  • The 5-year median for Return on Capital Employed is 0.07% (2025), against an average of 0.12%.
  • The largest annual shift saw Return on Capital Employed increased 28bps in 2024 before it tumbled -58bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.1% in 2021, then plummeted by -34bps to 0.13% in 2022, then soared by 63bps to 0.05% in 2023, then surged by 114bps to 0.01% in 2024, then plummeted by -8751bps to 0.58% in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Return on Capital Employed are 0.58% (Q4 2025), 0.29% (Q3 2025), and 0.2% (Q2 2025).